An issue of Endo International plc – (NASDAQ:ENDP) bonds rose 1.3% against their face value during trading on Thursday. The debt issue has a 6% coupon and will mature on July 15, 2023. The bonds in the issue are now trading at $85.55 and were trading at $87.25 last week. Price moves in a company’s bonds in credit markets often anticipate parallel moves in its share price.
A number of research firms recently issued reports on ENDP. Canaccord Genuity restated a “hold” rating and issued a $14.00 target price on shares of Endo International plc – in a report on Monday. Mizuho reiterated a “buy” rating and set a $18.00 price objective (up from $17.00) on shares of Endo International plc – in a research note on Thursday, April 13th. Royal Bank of Canada set a $15.00 price objective on shares of Endo International plc – and gave the stock a “hold” rating in a research note on Saturday, April 8th. Leerink Swann reiterated a “market perform” rating on shares of Endo International plc – in a research note on Monday, March 20th. Finally, JMP Securities reiterated an “outperform” rating and set a $20.00 price objective on shares of Endo International plc – in a research note on Wednesday, March 15th. Thirteen analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $20.72.
Shares of Endo International plc – (NASDAQ:ENDP) traded down 1.670% during midday trading on Friday, reaching $10.305. 4,660,100 shares of the company’s stock were exchanged. The company’s market capitalization is $2.30 billion. Endo International plc – has a 1-year low of $9.70 and a 1-year high of $35.34. The firm has a 50-day moving average of $10.84 and a 200-day moving average of $14.65.
Endo International plc – (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, February 28th. The company reported $1.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.14. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.17 billion. Endo International plc – had a positive return on equity of 15.95% and a negative net margin of 3.32%. The company’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.36 earnings per share. Equities analysts expect that Endo International plc – will post $3.60 earnings per share for the current fiscal year.
In other Endo International plc – news, Director Nancy J. Hutson sold 5,325 shares of the stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $10.82, for a total value of $57,616.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. raised its position in Endo International plc – by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares in the last quarter. Acrospire Investment Management LLC raised its position in Endo International plc – by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock worth $159,000 after buying an additional 4,597 shares in the last quarter. Perceptive Advisors LLC bought a new position in Endo International plc – during the fourth quarter worth $213,000. Americafirst Capital Management LLC bought a new position in Endo International plc – during the first quarter worth $286,000. Finally, Tyers Asset Management LLC bought a new position in Endo International plc – during the fourth quarter worth $375,000. Institutional investors own 95.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Endo International plc – (ENDP) Bond Prices Rise 1.3%” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/04/21/endo-international-plc-endp-bonds-trading-1-3-higher-updated-updated.html.
Endo International plc – Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
What are top analysts saying about Endo International plc -? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International plc - and related companies.